Drug profile · INN
dapsone
DAPSOMED
dapsone (DAPSOMED) is a dihydropteroate synthase 1 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — dapsone
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 2
- Programs
- 0
- Data quality
- 0.89
Quick answer
dapsone (DAPSOMED) is a dihydropteroate synthase 1 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydropteroate synthase 1 inhibitor
Primary target: Dihydropteroate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is dapsone?
dapsone (DAPSOMED) is a dihydropteroate synthase 1 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for dapsone?
DAPSOMED is a marketed brand name for dapsone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dapsone?
dapsone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.